What is Cortisol?
Cortisol is the body’s main stress hormone, produced by the adrenal glands and controlled by a feedback loop known as the hypothalamic-pituitary-adrenal (HPA) axis. In America in 2026, cortisol has moved from a topic doctors discussed quietly in endocrinology clinics to a subject millions of everyday Americans now search for, test, and try to manage on their own. The hormone plays a central role in regulating blood sugar, blood pressure, metabolism, immune response, and the sleep-wake cycle, rising naturally in the early morning and tapering off at night. When this rhythm is disrupted by chronic stress, poor sleep, or an underlying medical condition, the downstream effects can touch nearly every system in the body.
This growing awareness has reshaped how US cortisol statistics are generated and consumed. Employers, healthcare systems, wearable-technology companies, and the supplement industry are all now tracking cortisol-related stress, testing, and hormone levels as a measurable part of national health. From workplace burnout surveys to at-home saliva test kits and continuous wearable sensors, cortisol has become one of the most closely watched biomarkers of 2026. The sections below break down the latest verified US cortisol statistics 2026, covering testing volumes, market size, sleep and workplace stress links, clinical disorders tied to abnormal cortisol levels, and the technology now used to measure it.
Interesting Cortisol Facts in the US 2026
| Cortisol Fact | Figure / Data Point (2025-2026) |
|---|---|
| US/Canada daily workplace stress rate | 50% of employees report significant daily stress |
| Employed adults citing work as a significant stressor | 69% of US employed adults |
| Short sleep prevalence (a known cortisol disruptor) | 30.5% of US adults sleep under 7 hours nightly |
| Global cortisol testing market value (2026) | $2.25 billion, projected |
| North America share of the cortisol testing market | 42.1%, roughly $885 million in 2025 |
| US endocrine testing market (includes cortisol assays) | $4.84 billion in 2025 |
| Addison’s disease (low cortisol) prevalence in the US | 100 to 140 per million people |
| Cushing’s syndrome (high cortisol) incidence estimate | 7.2 to 48.6 cases per million person-years |
| US ashwagandha (adaptogen) supplement sales | Exceeded $500 million annually by 2024 |
| Global wearable sweat-biosensor market (2024) | $4.41 billion, cortisol among key tracked biomarkers |
| Normal morning blood cortisol reference range | 10-20 mcg/dL (6 a.m.-8 a.m. draw) |
Data sources: Gallup State of the Global Workplace 2026; American Psychological Association Stress in America 2025; CDC National Center for Health Statistics Data Brief No. 559 (2026); market research and endocrine testing industry analyses (2025-2026)
The figures above show that cortisol in 2026 sits at the intersection of everyday life and clinical medicine. On one end, half of US and Canadian workers report carrying significant daily stress, a psychological state directly tied to elevated cortisol output, while nearly a third of American adults get too little sleep, a second major trigger for HPA-axis disruption. These two overlapping patterns, workplace pressure and short sleep, form the backdrop against which most US cortisol statistics are now measured and marketed.
On the clinical and commercial end, the numbers reveal a hormone that has become a genuine growth market. Endocrine and cortisol-specific testing already represents billions of dollars in annual US healthcare spending, while rare cortisol disorders like Cushing’s syndrome and Addison’s disease, though statistically uncommon, continue to drive diagnostic demand. Meanwhile, consumer-facing industries, from ashwagandha supplements to wearable sweat sensors, have built entire product categories around helping Americans monitor and manage their own cortisol response outside a doctor’s office.
Cortisol Testing Market Statistics in the US 2026
US Endocrine & Cortisol Testing Market (USD, by year)
2025 ████████████████████ $4.84B
2026 ██████████████████████ $5.30B (est.)
2030 ███████████████████████████████ $7.10B (forecast)
2033 ███████████████████████████████████████ $8.92B (forecast)
| Market Segment | Value / Share (2025-2026) |
|---|---|
| US endocrine testing market size (2025) | $4.84 billion |
| Projected US endocrine testing market by 2033 | $8.92 billion |
| CAGR, 2026-2033 | 8.0% |
| North America cortisol testing market (2025) | $885 million |
| North America share of global cortisol testing | 42.1% |
| Largest test-type segment | Thyroid stimulating hormone (cortisol is second-tier by volume) |
| Fastest-growing test-type segment | DHEAS (dehydroepiandrosterone sulfate) test |
Data source: Endocrine and cortisol testing industry market analyses, 2025-2026.
The US cortisol and endocrine testing market is one of the largest in the world, anchored by companies like Quest Diagnostics, LabCorp, Abbott, and Thermo Fisher Scientific. North America alone accounts for over 42% of global cortisol testing revenue, reflecting both a well-developed healthcare infrastructure and rising patient-driven demand for hormone panels. While thyroid testing remains the single largest revenue segment inside the broader endocrine category, cortisol assays are growing steadily as primary care providers increasingly order them to rule out adrenal dysfunction in patients presenting with fatigue, weight changes, or unexplained blood pressure issues.
These figures, drawn from industry market analyses rather than a single government registry, should be read as estimates rather than confirmed clinical totals, since no federal agency publishes a unified count of every cortisol test ordered nationally. Even so, the consistent double-digit growth forecast through 2033 signals that cortisol testing is shifting from a niche endocrinology tool toward a mainstream diagnostic used across primary care, sports medicine, and mental health settings, a trend that mirrors the broader rise in preventive and wellness-driven lab testing across the United States.
Cortisol Levels and Normal Range Statistics in the US 2026
Typical Adult Cortisol Levels by Time of Day and Sample Type
Blood, 6-8am ██████████████████ 10-20 mcg/dL
Blood, ~4pm ████████ 3-10 mcg/dL
Saliva, morning ████████████████ 10.2-27.3 ng/mL
Saliva, night ███ 2.2-4.1 ng/mL
Urine, 24-hour ██████████████ 10-55 mcg/day
| Test Type | Normal Reference Range (Adult) |
|---|---|
| Blood cortisol, 6 a.m.-8 a.m. | 10-20 mcg/dL |
| Blood cortisol, around 4 p.m. | 3-10 mcg/dL |
| Saliva cortisol, morning | 10.2-27.3 ng/mL |
| Saliva cortisol, night | 2.2-4.1 ng/mL |
| Urine cortisol, 24-hour collection | 10-55 mcg/day |
| Elevated flag threshold (common lab cutoff) | Above 19.4 mcg/dL at morning draw |
Data source: Clinical laboratory reference ranges compiled from WebMD and peer-reviewed endocrinology publications, 2025-2026.
Cortisol levels follow a predictable daily rhythm in healthy adults, peaking shortly after waking and gradually declining through the day, a pattern known as the diurnal cortisol curve. Because levels can vary by lab, sample type, age, medication use, and even oral contraceptive use, the reference ranges above are general benchmarks rather than fixed cutoffs, and clinicians typically interpret results alongside symptoms and repeat testing rather than a single number.
Saliva testing has become increasingly popular for at-home cortisol monitoring because it is non-invasive and better reflects “free,” biologically active cortisol rather than the protein-bound form measured in standard blood draws. Blood testing remains the clinical gold standard for diagnosing conditions like Cushing’s syndrome or adrenal insufficiency, however, because it allows for dynamic stimulation and suppression testing that saliva sampling cannot replicate with the same precision, which is why most formal diagnoses still begin with a morning blood draw.
Workplace Stress and Cortisol Statistics in the US 2026
Daily Stress Rate by Region (Gallup 2026)
US & Canada ██████████████████████████ 50%
Global average ██████████████████████ 44%
Europe ████████████████████ 39%
| Workplace Stress Metric | 2025-2026 Figure |
|---|---|
| US/Canada daily significant stress rate | 50% of employees |
| Global average daily stress rate | 44% of employees |
| US employed adults citing work as significant stressor | 69% |
| Americans reporting work-related stress (OSHA data) | 83% of US workers |
| Americans citing money as a significant stressor | Roughly two-thirds of adults |
| US/Canada employees classified as “thriving” | 51%, a regional low |
Data sources: Gallup State of the Global Workplace 2026; American Psychological Association Stress in America 2025; Occupational Safety and Health Administration.
The link between workplace stress and cortisol is one of the most consistent findings in occupational health research, since psychological stress reliably activates the HPA axis and raises circulating cortisol. Gallup’s 2026 workplace data shows the United States and Canada recording the highest daily stress rate of any global region at 50%, unchanged year over year, while barely half of employees in the region now describe themselves as thriving, a first-time low since Gallup began tracking the metric. For readers exploring related occupational figures in more depth, the Workplace Stress Statistics in the U.S report breaks down the data further by industry and role.
The APA’s most recent Stress in America survey reinforces this picture from the individual’s perspective: 69% of employed US adults say their job is a significant source of stress, and roughly two-thirds point to money as a leading pressure point. Because chronic psychological stress is one of the most reliable non-clinical drivers of elevated baseline cortisol, these workplace figures function as an indirect but scientifically grounded proxy for population-level cortisol exposure across the American labor force in 2026.
Sleep Deprivation and Cortisol Statistics in the US 2026
US Adults Reporting Short Sleep (<7 hrs/night), 2024 NHIS Data
Overall adults ███████████████ 30.5%
Ages 45-64 █████████████████ 39%
Native Hawaiian/PI ████████████████████ 49%
| Sleep Metric | 2024-2026 Figure |
|---|---|
| US adults sleeping under 7 hours nightly | 30.5% |
| Adults 45-64 not getting enough sleep | 39% |
| Native Hawaiian/Pacific Islander adults affected | 49% |
| Range across US states | 30% to 46% of adults |
| US adults with obstructive sleep apnea (2024 estimate) | 32.4%, roughly 83.7 million adults |
| Estimated annual economic cost of sleep deprivation | Up to $411 billion |
Data source: CDC National Center for Health Statistics, NHIS Data Brief No. 559, April 2026.
Sleep and cortisol are tightly linked through the HPA axis, and the CDC’s newest national data, published in April 2026, shows that 30.5% of US adults, roughly one in three, still sleep less than the recommended seven hours a night, a figure that has barely moved in over a decade despite growing public awareness. Insomnia and chronic sleep restriction are associated with a 24-hour increase in cortisol and ACTH secretion, consistent with a state of central nervous system hyperarousal, according to NIH-published endocrinology research, meaning poor sleep does not just result from stress but can actively perpetuate elevated cortisol the following day.
The relationship is not simple, however. Peer-reviewed meta-analyses of controlled sleep-deprivation studies have found inconsistent effects on cortisol, with some showing a next-day evening rise and others showing a decrease, suggesting sleep’s influence on cortisol depends heavily on whether restriction is acute or chronic. This nuance matters for anyone using US sleep statistics to draw conclusions about population-wide cortisol trends, since short-term lab findings do not always mirror the cumulative, real-world impact of years of inadequate sleep documented in national health surveys.
Cushing’s Syndrome and High Cortisol Statistics in the US 2026
Cushing's Syndrome Incidence Estimates (per million person-years)
Historical European estimate ███ 1-3
US MarketScan (commercial ins.) ███████████████████████ 48.6
US regional study (Wisconsin) ██████ 7.2 (minimum)
| Cushing’s Syndrome Metric | Figure |
|---|---|
| Historical incidence estimate (older studies) | 1 to 3 per million person-years |
| US commercially-insured incidence (MarketScan data) | 48.6 per million person-years |
| Minimum US regional incidence (Wisconsin study) | 7.2 per million patient-years |
| Female-to-male ratio | Roughly 3:1 |
| Highest-incidence age group | 35 to 44 years old |
| US prevalence estimate, all forms | Under 20,000 people |
Data source: Peer-reviewed endocrinology and epidemiology research (PubMed, Medscape), 2013-2024.
Cushing’s syndrome, the clinical condition caused by chronically elevated cortisol, has long been described as rare, but newer US-based research suggests it may be considerably more common than older European estimates implied. A widely cited MarketScan claims-database analysis of the commercially insured US population under age 65 found incidence rates of 48.6 cases per million person-years, far above the 1-to-3-per-million figure drawn from older international studies, while a more recent single-institution Wisconsin analysis found a minimum incidence of 7.2 cases per million patient-years, with adrenal-based Cushing’s syndrome outnumbering the pituitary form for the first time in the literature. Readers researching treatment pathways for this condition can find additional detail in the Cushing’s Disease Treatments in US guide, along with related symptom coverage in the Buffalo Hump Statistics in US report, since a fatty hump at the base of the neck is one of the classic physical markers of chronic hypercortisolism.
Importantly, newer research also found that fewer than half of patients with adrenal Cushing’s syndrome displayed the classic physical features typically taught in medical training, such as the rounded face, weight gain, or stretch marks historically associated with the condition. This gap between textbook presentation and real-world patient appearance is a likely contributor to underdiagnosis, and it helps explain why US prevalence figures remain genuinely uncertain even as incidence estimates climb, a caveat that official US health agencies still openly acknowledge in current publications.
Addison’s Disease and Low Cortisol Statistics in the US 2026
Adrenal Insufficiency Prevalence (per million population)
Primary (Addison's disease) ████████████ 100-140
Secondary adrenal insufficiency ████████████████████████ 150-280
| Adrenal Insufficiency Metric | Figure |
|---|---|
| Addison’s disease prevalence (developed countries) | 100 to 140 per million |
| Secondary adrenal insufficiency prevalence | 150 to 280 per million |
| Share of Addison’s cases from autoimmune causes | Roughly 80-90% |
| Typical age of onset | 30 to 50 years old |
| New cases per year (incidence) | 4.4 to 6.2 per million, annually |
| Autoimmune Addison’s patients developing a second autoimmune disorder | About 50%, lifetime risk |
Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 2025-2026.
On the opposite end of the cortisol spectrum, Addison’s disease, or primary adrenal insufficiency, remains a rare but medically serious condition in which the adrenal glands fail to produce enough cortisol. According to the NIDDK, part of the National Institutes of Health, the disease affects an estimated 100 to 140 people per million in developed countries like the United States, while the more common secondary form, caused by pituitary or hypothalamic dysfunction rather than adrenal gland failure itself, affects 150 to 280 people per million. Because roughly 80 to 90% of Addison’s cases stem from autoimmune destruction of the adrenal cortex, patients often benefit from broader hormone-health context, such as the trends covered in the Testosterone Replacement Statistics in US report, given how frequently multiple endocrine systems are affected together.
Diagnosis remains genuinely difficult because early symptoms, including fatigue, salt cravings, and low blood pressure, are vague and easily mistaken for more common conditions. The NIDDK explicitly notes that there are no fully accurate incidence statistics for the United States, since undiagnosed and misdiagnosed cases likely go uncounted, meaning the official prevalence figures should be treated as a conservative floor rather than a precise national census of everyone actually living with clinically low cortisol.
Wearable Cortisol Sensor Statistics in the US 2026
Global Wearable Sweat Biosensor Market (USD, includes cortisol tracking)
2024 ███████████████ $4.41B
2034 █████████████████████████████████████ $13.47B (forecast)
| Wearable Technology Metric | Figure |
|---|---|
| Global wearable sweat-sensor market (2024) | $4.41 billion |
| Projected market by 2034 | $13.47 billion |
| CAGR, 2024-2034 | 11.8% |
| Cortisol concentration range detectable in sweat | 0.1 to 25 ng/mL |
| Leading US/global R&D institutions | Caltech, Tufts, Baylor University |
| Commercial approach used most commonly today | Sweat-based lateral flow assay patches |
Data source: ACS Materials Letters wearable sweat-sensor review; IEEE Spectrum and Nature Sensors reporting, 2026.
Continuous, non-invasive cortisol monitoring is one of the fastest-moving frontiers in US health technology, with companies like EnLiSense, Biolinq, and Adaptyx developing patches capable of tracking the stress hormone directly through sweat or interstitial fluid rather than a single lab draw. Recent peer-reviewed work published in Nature Sensors describes wearable devices that can resolve circadian cortisol variation, acute stress responses, and jet-lag-related disruption in real time, closely matching results from traditional saliva and serum assays, a technical milestone that had eluded researchers for years due to the extremely low concentration of cortisol present in sweat.
The broader wearable sweat-biosensor category, which includes cortisol alongside glucose, lactate, and electrolyte tracking, is forecast to nearly triple in global market value from $4.41 billion in 2024 to $13.47 billion by 2034, and the United States remains one of the two leading countries in both patent filings and clinical research output in this space. As with any fast-moving hardware category, these are still largely research-stage and early-commercial figures rather than mass-market retail sales, so consumers should expect continued FDA-related regulatory milestones before fully validated cortisol wearables become as common as today’s glucose or heart-rate monitors.
Cortisol Supplement Market Statistics in the US 2026
| Supplement Market Metric | Figure |
|---|---|
| Global stress-relief supplement market (2025) | $629.93 million |
| Projected global market by 2033 | $1.07 billion |
| US ashwagandha supplement sales (2024) | Over $500 million annually |
| Adaptogen share of the stress-relief ingredient market | 30% |
| Personalized stress-supplement segment (2026 projection) | $1.2 billion, growing 18.3% CAGR |
| North America’s share of global adaptogen demand | Largest single region |
Data source: DataM Intelligence, Fortune Business Insights, and adaptogen industry market reports, 2025-2026.
The commercial response to rising cortisol awareness has been substantial, with adaptogenic herbs like ashwagandha, rhodiola, and shatavari now marketed specifically for “cortisol support” across mainstream retailers, not just specialty wellness shops. US ashwagandha sales alone crossed $500 million annually by 2024, and adaptogens now represent roughly 30% of the entire stress-relief supplement ingredient category, reflecting how thoroughly cortisol-focused messaging has penetrated everyday consumer health marketing. Shoppers comparing these products to other everyday hormone and wellness supplements may also find the Multivitamin Statistics in US report useful for understanding broader US supplement-spending patterns.
It is worth noting that most cortisol-support supplements are not FDA-approved to diagnose, treat, or cure any cortisol-related medical condition, and the clinical evidence behind specific adaptogens remains mixed even as sales climb. Regulatory scrutiny is also increasing, with the FTC pushing for better-substantiated health claims across the adaptogen category, a trend likely to shape how “cortisol-balancing” products are marketed to American consumers through the remainder of 2026 and beyond.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
